



Harness the Power of Lipid Nanoparticles (LNPs) for Next-Gen Therapeutics!

Discover the potential of nucleic acid therapeutics with our cutting-edge LNP platform. Collaborate with us to benefit from advanced RNA delivery technologies and extensive expertise.

Our comprehensive suite of **analytical tools** offers insights into:

- *In vitro* delivery mechanisms
- *In vivo* biodistribution patterns
- Tissue targeting efficacy
- Immune response dynamics and tolerability

Our Key Services:

- Bioluminescence *in vivo* imaging for real-time monitoring of RNA delivery
- Detection and visualization techniques including single-cell barcode sequencing, RNAscope™, qPCR, and immunohistochemistry (IHC)

Ensure Safety:

- Assess the tolerability of novel LNPs with *ex vivo* cytokine profiling, liver enzyme profiling, and complement activation assessment. Choose from safety packages or single toxicology studies tailored to your needs!

Contact us

NUVISAN ICB GmbH
Muellerstr. 178
13353 Berlin, Germany

Web: www.nuvisan.com
Email: hello@nuvisan.com
LinkedIn: [company/nuvisan](https://www.linkedin.com/company/nuvisan)



Explore Our LNP Delivery Platform!

Advanced *In Vitro* Delivery Analysis:

Unlock the potential of your lipid nanoparticle (LNP) formulations with our high-content analysis, offering detailed insights into cellular LNP entry, endosomal escape, and RNA translation. Our multiplexed assays enable simultaneous measurement of three critical cellular steps:

LNP Uptake:

- Quantification of Cy5-labelled RNA delivered by LNPs

Endosomal Escape:

- Utilization of fluorescent Gal9 reporter for precise assessment

Delivery:

- Evaluation of GFP expression from delivered RNA
- Versatile assay system adaptable to various cell lines, including those from different tissues or iPSCs

***In Vivo* Biodistribution Assessment:**

- Bioluminescence *in vivo* imaging of LNP:luc mRNA (BLI)
- *Ex vivo* analyses
- Single-cell sequencing
- hEPO (ELISA)
- RNA in situ hybridization (RNAscope™)
- Target mRNA quantification (qPCR), and IHC

Tolerability Assessment:

Ensure safety and tolerability with our comprehensive studies via:

- Cytokine profiling
- Liver enzyme profiling
- Complement activation

Tailored safety packages or single toxicology studies. Available in both non-GLP and GLP formats.

Contact us

NUVISAN ICB GmbH
Muellerstr. 178
13353 Berlin, Germany

Web: www.nuvisan.com
Email: hello@nuvisan.com
LinkedIn: [company/nuvisan](https://www.linkedin.com/company/nuvisan)